Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
UNICANCER
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04053322CT.gov Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | — | Active Not Recruiting | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · DNA Repair Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | UNICANCER | P2 | CCC · 53 |
| Fluorouracilum | National Cancer Institute (NCI) | P3 | B |
| Atezolizumab | National Cancer Institute (NCI) | P3 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P3 | B |
| Durvalumab | UNICANCER | P2 | CCC |
| Prednisolone | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P2 | CCC |
| Prednisone | Northwestern University | P2 | CCC |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P2 | CCC |
| Abiraterone | Northwestern University | P2 | CCC |
+7 more in the DNA Repair Disease cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in DNA Repair Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-dna-repair-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →